KSKai Sun

Kai Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kai Sun has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic

    by Dahima Cintron, Caitlan Pinotti, Jennifer L Rogers, Kai Sun, Rebecca Sadun, Mithu Maheswaranathan, Jayanth Doss, Lisa Criscione-Schreiber, Megan E.B. Clowse

    Background/Purpose: Mycophenolate compound (MMF, to represent both mycophenolate mofetil and mycophenolic acid) is an immunosuppressant used to treat Systemic Lupus Erythematosus (SLE). Due to its teratogenicity, the FDA recommends universal mycophenolate Risk Evaluation and Mitigations Strategies (MREMS) to prevent unplanned pregnancies and minimize fetal exposure. This quality improvement initiative aimed to improve documentation of the MREMS protocol in the encounter clinic note from 0% to 75% within 14 months. Methods: The project was conducted in an academic lupus clinic from February 2023 to May 2024, with the intervention beginning in March 2023. MREMS was recommended for adult female SLE patients aged 18–50 on MMF, excluding those with hysterectomy. Interventions included provider and nurse education, nursing algorithms for identifying eligible patients and ordering pregnancy tests, electronic health record template updates, and regular feedback. Required documentation included counseling on MMF teratogenicity and contraception, with pregnancy testing at each visit. Control charts monitored documentation of MREMS counseling and pregnancy testing, and a one-year post-implementation follow-up was completed. Results: Among eligible encounters ( n = 89), MREMS documentation increased from 0% to an average of 24% during the first 8 months of PDSA cycles, then shifted to an average of 67% of encounters. We reached and sustained our documentation goal of 75% for the last three consecutive months. Pregnancy-test ordering rose from 0% to 63%, and contraception was documented at 98% of visits. Over the course of the intervention, no pregnancies were exposed to MMF. MREMS documentation and pregnancy screening remained above 75% of encounters 1 year after intervention. Conclusion: Using quality improvement cycles, we incorporated a two-part MREMS protocol into a busy academic lupus clinic, with improved documentation and pregnancy screening.


  • Differences in Self-Reported Medication Nonadherence and Its Drivers in Young Adults Versus Older Adults With Systemic Lupus Erythematosus

    by Hannah R. Concannon, Kai Sun, Jennifer L. Rogers, Megan E.B. Clowse, Rachel L. Randell, Mithu Maheswaranathan, Lisa G. Criscione-Schreiber, Nathaniel J. Harris, Amanda M. Eudy, Rebecca E. Sadun

    Objective: Medication adherence poses a challenge for young patients with systemic lupus erythematosus (SLE), who experience more active disease and damage than their older counterparts. This study aimed to quantify the rate of medication nonadherence by age and to identify differences in reasons for nonadherence between younger and older patients with SLE. Methods: We collected responses to the Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence)-SLE questionnaire, a clinical tool validated to measure extent of and reasons for medication nonadherence in SLE. Analysis included 336 surveys completed between February 2020 and June 2024. Proportions and odds ratios (ORs) for extent of and reasons for nonadherence were determined across age groups, and logistic regression was used to determine relationships of nonadherence with age and other covariates. Results: Medication nonadherence differed significantly across age groups 18-29, 30-39, 40-49, and 50+ ( P < 0.001). For each increased year of age, self-reported nonadherence decreased by 2% ( P < 0.05). Black race and Hispanic ethnicity were also predictive of nonadherence across age groups. The < 30 age group was more likely to report nonadherence due to inability to fill medications on time (OR 3.72, 95% CI 1.53-9.02) and needing to take medicines with food (OR 2.55, 95% CI 1.06-6.13). Conclusion: Younger patients reported greater extent of nonadherence, often due to logistical impediments. In addition to counseling young adults with SLE on the importance of medications, rheumatologists should, when possible, offer support to help them overcome challenges in obtaining and taking medicines. Approaches to understanding and intervening on medication nonadherence in SLE may need to be tailored by age.


  • Open Access

    Reduced late endosome/lysosome function promotes SLE through chronic PI3K activity and SHP-1/SHIP-1 defects

    by SunAh Kang, Andrew J. Monteith, Liubov Arbeeva, Karissa Grier, Shruti Saxena Beem, Anthony C. Trujillo, Xinyun Bi, Kai Sun, Rebecca E. Sadun, Mithu Maheswaranathan, et al.

    Degradation of cellular waste from phagocytosis, endocytosis, and autophagy occurs through hydrolases that become activated during acidification of late endosomes and lysosomes (LELs). In our cross-sectional study, we showed diminished LEL acidification and the accumulation of surface-bound nucleosome on monocytes, dendritic cells, B cells, neutrophils, and T cells from patients with systemic lupus erythematosus (SLE). Diminished acidification and exocytosis of undegraded IgG-immune complexes were evident in active, but not inactive, disease. This was supported by our murine study in which LEL acidification was diminished, promoting exocytosis and the accumulation of cell surface IgG-immune complexes. Mechanistically, LEL dysfunction was induced by chronic PI3K activation in lupus-prone MRL/ lpr mice. We also showed that on a non-autoimmune C57BL/6 background, deficiency in SHP-1 and inhibition of SHIP-1 activity were sufficient to recapitulate LEL dysfunction found in MRL/ lpr mice. Non-acidic LELs were evident in the majority of patients and associated with SLEDAI arthritis, rash, and nephritis. The high frequency of LEL dysfunction in SLE suggests that it could serve as a biomarker identifying a specific disease endotype.


  • Racial differences in medication beliefs and adherence barriers among patients with systemic lupus erythematosus

    by Shivani Rangaswamy, Amanda M. Eudy, Megan E.B. Clowse, Jennifer Rogers, Rebecca E. Sadun, Lisa G. Criscione-Schreiber, Jayanth Doss, Mithu Maheswaranathan, Nathaniel Harris, Dana R. Burshell, et al.

    Introduction: Black patients with systemic lupus erythematosus (SLE) have lower medication adherence than White patients, contributing to worse health outcomes. However, racial differences in reasons for nonadherence and beliefs about medications are not well understood. Methods: We conducted a cross-sectional analysis of Black and White patients with SLE who completed the Beliefs about Medicines Questionnaire and the SLE-specific Domains of Subjective Extent of Nonadherence survey. We compared scores by race and by adherence level within each racial group. Results: Among 123 patients (52% Black, 48% White), adherence was lower in Black patients (44% vs 64%, p = .02). Black patients reported greater concerns about SLE medications and medication overuse and harm than White patients. Nonadherent Black patients reported weaker beliefs in SLE medication necessity and greater concerns about medication overuse and harm than adherent Black patients. Reasons for nonadherence reported by Black patients but not White patients included feeling well (45%), concerns about future fertility (14%), and doubts about their doctors and medicines (8%). Conclusion: Nonadherence among Black patients was uniquely associated with stronger concerns about medication overuse and harm and weaker beliefs that SLE medicines were necessary, potentially reflecting medical mistrust that may drive skipping doses when feeling well or when concerns arise. These insights can help clinicians more astutely probe and address each patient’s needs to enhance medication adherence and SLE management.


  • Open Access

    Relationship between hydroxychloroquine blood levels and lupus activity through the lens of the type 1 and type 2 lupus model: a cross-sectional study

    by Kai Sun, Amanda M Eudy, Megan E B Clowse, Stephen J Balevic, Tyler O’mAlley, Roberta Vezza Alexander, Rebecca E Sadun, Mithu Maheswaranathan, Jayanth Doss, Lisa G Criscione-Schreiber, et al.

    Introduction: In the type 1 and 2 SLE model, inflammation mediates type 1 manifestations, but its role in type 2 manifestations (eg, fatigue, myalgias, mood disturbance, cognitive dysfunction) is less clear. Therapeutic hydroxychloroquine (HCQ) levels reduce type 1 activity, but their relationship with type 2 activity is unknown. Exploring this relationship may illuminate type 2 SLE pathophysiology. Methods: We measured whole blood HCQ levels using liquid chromatography–mass spectrometry, categorising them as underexposure (minimal (low type 1 and type 2), type 1 (high type 1 and low type 2), type 2 (low type 1 and high type 2) and mixed activity (high type 1 and type 2) groups. We analysed relationships between HCQ levels and type 1 and type 2 SLE activities. Results: Among 154 patients (median age 43, 90% women, 63% Black race, 7% Hispanic ethnicity) across 297 visits, HCQ levels were underexposed at 41 (14%) visits, subtherapeutic at 76 (26%) and therapeutic at 180 (61%) visits. Patients had minimal activity at 102 visits (34%), type 1 activity at 33 (11%), type 2 activity at 85 (29%) and mixed activity at 77 (26%) visits. Underexposed HCQ levels were independently associated with higher type 1 (OR 2.33, 95% CI 1.23 to 4.44) and type 2 activities (OR 1.80, 95% CI 1.07 to 3.04). Mixed activity most strongly associated with Underexposed HCQ levels (OR 3.4–10.3, pmixed activity group, suggesting that immunologic activity may contribute to type 2 symptoms in some patients.


  • Open Access

    Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model

    by Amanda M. Eudy, Megan E. B. Clowse, Amy Corneli, Summer Starling, Nneka Jebose Molokwu, Teresa Swezey, David S. Pisetsky, Mithu Maheswaranathan, Jayanth Doss, Kai Sun, et al.

    Objective: The Type 1 and 2 systemic lupus erythematosus (SLE) Model was developed to encapsulate all signs and symptoms that patients with SLE experience. Our previous qualitative work demonstrated the model accurately reflects the lived experience of people living with SLE. The objective of this study was to present the Type 1 and 2 SLE Model to rheumatologists to understand how the model fits with their experiences treating patients with SLE.Methods: We conducted a qualitative descriptive study using semistructured interviews with rheumatologists. Rheumatologists were asked about their general impression of the Type 1 and 2 SLE Model, how the model does or does not fit within their approach to treating patients with SLE, the utility of the model in clinical practice, and any suggested changes. Applied thematic analysis identified salient themes.Results: We interviewed 13 rheumatologists. The majority of rheumatologists approved of the model and found it useful to guide therapy and clinical decision‐making. Several rheumatologists thought the model was helpful for patient education to manage expectations about differences between Type 1 and Type 2 symptoms and treatments. A few rheumatologists expressed concern that the model could lead to an overdiagnosis of SLE.Conclusion: The Type 1 and 2 SLE Model was accepted by most rheumatologists interviewed and welcomed as a useful approach to identifying and treating symptoms in patients with SLE. Future studies will determine how implementing the Type 1 and 2 SLE Model affects patient understanding, the physician–patient relationship, and clinical outcomes.


  • Using linked electronic medical record-pharmacy data to examine lupus medication adherence: A retrospective cohort study

    by Kai Sun, Daniel Wojdyla, Ankoor Shah, Amanda M Eudy, Megan Eb Clowse

    Introduction: Medication nonadherence is common in systemic lupus erythematosus (SLE) and associated with morbidity and mortality. We explored the reliability of pharmacy data within the electronic medical record (EMR) to examine factors associated with nonadherence to SLE medications. Methods: We included patients with SLE who were prescribed ≥1 SLE medication for ≥90 days. We compared two datasets of pharmacy fill data, one within the EMR and another from the vendor who obtained this information from pharmacies and prescription benefit managers. Adherence was defined by medication possession ratio (MPR) ≥80%. In addition to MPR for each SLE medication, we evaluated the weighted-average MPR and the proportion of patients adherent to ≥1 SLE medication and to all SLE medications. We used logistic regression to examine factors associated with adherence. Results: Among 181 patients (median age 36, 96% female, 58% Black), 98% were prescribed hydroxychloroquine, 34% azathioprine, 33% mycophenolate, 18% methotrexate, and 7% belimumab. Among 1276 pharmacy records, 74% overlapped between linked EMR-pharmacy data and data obtained directly from the vendor. Only 9% were available from the vendor but not through linked EMR-pharmacy data. The weighted-average MPR was 57%; 45% were adherent to hydroxychloroquine, 46% to ≥1 SLE medication, and 32% to all SLE medications. Older age was associated with adherence in univariable and multivariable analyses. Discussion: Our study showed that obtaining linked EMR-pharmacy data is feasible with minimal missing data and can be leveraged in future adherence research. Younger patients were more likely to be nonadherent and may benefit from targeted intervention.


  • Implementation of a Clinician-led Medication Adherence Intervention Among Patients With Systemic Lupus Erythematosus

    by Kai Sun, Nneka Jebose Molokwu, Emily Hanlen-Rosado, Amy L. Corneli, Kathryn I. Pollak, Jennifer L. Rogers, Rebecca E. Sadun, Lisa G. Criscione-Schreiber, Jayanth Doss, Hayden B. Bosworth, et al.

    Objective: Medication nonadherence in systemic lupus erythematosus (SLE) leads to poor clinical outcomes. We developed a clinician-led adherence intervention that involves reviewing real-time pharmacy refill data and using effective communication to address nonadherence. Prior pilot testing showed promising effects on medication adherence. Here, we describe further evaluation of how clinicians implemented the intervention and identify areas for improvement.Methods: We audio recorded encounters of clinicians with patients who were nonadherent (90-day proportion of days covered [PDC] < 80% for SLE medications). We coded recordings for intervention components performed, communication quality, and time spent discussing adherence. We also conducted semistructured interviews with patients and clinicians on their experiences and suggestions for improving the intervention. We assessed change in 90-day PDC post intervention.Results: We included 25 encounters with patients (median age 39, 100% female, 72% Black) delivered by 6 clinicians. Clinicians performed most intervention components consistently and exhibited excellent communication, as coded by objective coders. Adherence discussions took an average of 3.8 minutes, and 44% of patients had ≥ 20% increase in PDC post intervention. In structured interviews, many patients felt heard and valued and described being more honest about nonadherence and more motivated to take SLE medications. Patients emphasized patient-clinician communication and financial and logistical assistance as areas for improvement. Some clinicians wanted additional resources and training to improve adherence conversations.Conclusion: We provide further evidence to support the feasibility, acceptability, and fidelity of the adherence intervention. Future work will optimize clinician training and evaluate the intervention’s effectiveness in a large, randomized trial.


  • Open Access

    Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study

    by Stephen Balevic, Kai Sun, Jennifer L Rogers, Amanda Eudy, Rebecca Eli Sadun, Mithu Maheswaranathan, Jayanth Doss, Lisa Criscione-Schreiber, Tyler O'Malley, Megan Clowse, et al.

    Objective Characterise the relationship between hydroxychloroquine (HCQ) blood levels and the number of missed doses, accounting for dosage, dose timing and the large variability in pharmacokinetics (PK) between patients. Methods We externally validated a published PK model and then conducted dosing simulations. We developed a virtual population of 1000 patients for each dosage across a range of body weights and PK variability. Using the model, 10 Monte Carlo simulations for each patient were conducted to derive predicted whole blood concentrations every hour over 24 hours (240 000 HCQ levels at steady state). To determine the impact of missed doses on levels, we randomly deleted a fixed proportion of doses. Results For patients receiving HCQ 400 mg daily, simulated random blood levels Conclusions We propose an algorithm to optimally interpret HCQ blood levels and approximate the number of missed doses, incorporating the impact of dosage, dose timing and pharmacokinetic variability. No single cut-off has adequate combinations of both sensitivity and specificity, and cut-offs are dependent on the degree of targeted non-adherence. Future studies should measure trough concentrations to better identify target HCQ levels for non-adherence and efficacy.


  • The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus

    by Amanda M Eudy, Megan Eb Clowse, Amy Corneli, Kevin McKenna, David S Pisetsky, Mithu Maheswaranathan, Dana Burshell, Jayanth Doss, Kai Sun, Rebecca E Sadun, et al.

    Objective: In the new Type 1 & 2 model for systemic lupus erythematosus (SLE), Type 1 SLE represents classic inflammatory manifestations, such as arthritis, while Type 2 SLE encompasses symptoms such as pain and fatigue where the relationship to inflammation is less clear. The objective of this study was to interview individuals living with SLE to determine the content and face validity of the Type 1 & 2 SLE model. Methods: We conducted a qualitative study using semi-structured interviews with a purposeful sample of participants who met classification criteria for SLE. Participants were asked to describe their experiences with Type 1 & 2 SLE symptoms and treatments, and they indicated if and how their personal experiences aligned with the Type 1 & 2 SLE model. All interviews were audio-recorded and transcribed; applied thematic analysis identified the most frequent and salient themes. Results: We interviewed 42 participants with SLE. Type 2 SLE symptoms, such as pain and fatigue, were very common, with almost all participants experiencing some Type 2 symptoms at some point during their disease course. Participants described Type 1 SLE symptoms as being acute flares and life-threatening and Type 2 SLE symptoms as “everyday lupus” that affected their daily lives and were a dominant part of their SLE disease experience. Most participants stated they want their rheumatologists to discuss Type 2 symptoms during clinical appointments in order to address their full symptom experience. Conclusion: We demonstrated content and face validity of the Type 1 & 2 SLE model with people living with SLE. Participants in our study largely understood the model and felt it accurately reflected their experience living with SLE. Type 2 SLE symptoms are very common in individuals with SLE and impact patients’ quality of life. Using the model to address Type 2 SLE symptoms allows the rheumatologist to incorporate the patient’s perspective and provide patient-centered care.